Compare Adaptive Biotechnologies Corp (ADPT) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.8. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | RDTE | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $22.37 | $34.73 |
52-Week Low | $10.24 | $26.40 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
RDTE trades at $29.33 with a slight 0.55% daily gain. Technical indicators show mixed signals with a neutral overall rating, while moving averages suggest a bullish bias. The stock has demonstrated consistent dividend payments throughout 2026, though key valuation metrics remain unavailable. Recent news highlights concerns about the ETF's structural risks and capital erosion potential despite high yield characteristics.
The outlook remains cautious given structural concerns about the covered call strategy's limitations. While regular dividends provide income appeal, the strategy's capped upside and full downside exposure present significant risk factors that may outweigh yield benefits for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
